Toxic effects of multiple anticancer drugs on skin

Pakistan Journal of Pharmaceutical Sciences

Volumn 23, Issue 1, 2010, Pages 7-14

  Kamil, Noor ^a   Kamil, Saba ^b   Ahmed, Shahida P ^c   Ashraf, Rizwan ^d   Khurram, Mohammad ^a   Ali, Muhammad Obaid ^e  

^a DOW UNIVERSITY OF HEALTH SCIENCES   (Pakistan)

^b AGA KHAN UNIVERSITY HOSPITAL   (Pakistan)

^c UNIVERSITY OF KARACHI   (Pakistan)

^d KING KHALID UNIVERSITY   (Saudi Arabia)

^e Ministry of Health Pakistan   (Pakistan)

Author keywords

Alopecia; Anticancer chemotherapy; Cutaneous toxicity; Cytotoxicity; Hyperpigmentation

Indexed keywords

ALKYLATING AGENT; ALPHA INTERFERON; ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; ASPARAGINASE; BLEOMYCIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DAUNORUBICIN; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; HYDROXYUREA; IDARUBICIN; IFOSFAMIDE; MEPREDNISONE; MERCAPTOPURINE; MESNA; METHOTREXATE; MITOXANTRONE; PREDNISONE; PROCARBAZINE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE NONLYMPHOCYTIC LEUKEMIA; ALOPECIA; ALTERNATIVE MEDICINE; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; DRUG HYPERSENSITIVITY; DRUG TARGETING; DRY SKIN; ERYTHEMA MULTIFORME; FEMALE; GROWTH ACCELERATION; HAND FOOT SYNDROME; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NAIL DISEASE; NONHODGKIN LYMPHOMA; PETECHIA; PHOTOSENSITIVITY; PRURITUS; SKIN TOXICITY; TARGET CELL; URTICARIA; WOUND INFECTION;

ALOPECIA; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; SKIN; SKIN DISEASES;

EID: 75649111955     PISSN: 1011601X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Alley E, Green R and Schuchter L (2002). Cutaneous toxicities of cancer therapy. Curr Opin. Oncol., 14(2): 212-216.
2. Bonati M, Choonara I, Hoppu K, Pons G and Seyberth H (1999). Closing the gap in drug therapy. Lancet., 355: 1625.
3. Branzan AL, Landthaler M, Szeimies RM. (2005). Skin changes with chemotherapy. Hautarzt., 56(6): 591-602.
4. Breathnach SM (1998). Drug reactions, in Rook/Wilkinson/Ebling Textbook of Dermatology (Champion RH, Burton JL, Burns DA and Breathnach SM eds.), Blackwell Science, Malden, MA. Pp.3349-3517.
5. th ed. McGraw-Hill, New York, pp.1381-1388.
6. Chabner BA. (2006). Clinical strategies for cancer treatment: The role of drugs. In: Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy. Principles and Practice, 4th ed. Lippincott Williams & Wilkins, Philadelphia, pp.1-14.
7. Chandha V and Shenoi SD (2004). Hair loss in cancer chemotherapeutic patients. Indian J. Dermatol. Venereol. Leprol., 69: 131-132.
8. Conroy S, et al. (2000). Unlicensed and off-label drug use in paediatric wards in different European countries. Br. Med. J., 320: 79-82.
9. Crowson AN, Brown TJ and Magro CM (2003). Progress in the understanding of the pathology and pathogenesis of cutaneous drug eruptions: implications for pathogenesis. Am. J. Clin. Dermatol., 4: 407-428.
10. Crowson AN and Magro CM. (1999). Lichenoid and subacute cutaneous lupus erythematosus-like dermatitis associated with antihistamine therapy. J. Cutan. Pathol., 26: 95-99.
11. Crowson AN and Magro CM (1999). Recent advances in the pathology of cutaneous drug eruptions. Dermatol. Clin., 17: 537-560.
12. DeSpain JD (1992). Dermatologic toxicity of chemotherapy. Semin Oncol. 19: 501-507.
13. th ed. Lippincott-Raven, Philadelphia, PA, pp.1201-1209.
14. Edwards IR and Aronson JK (2000). Adverse drug reactions: Definitions, diagnosis and management. Lancet, 356: 1255-1259.
15. Finley RS, et al. (2001). Hematologic Malignancies. In: Applied
16. Therapeutics: The Clinical Use of Drugs. Koda-Kimble MA, Young LY (eds.). Lippincott Williams & Wilkins, Philadelphia, pp.88-1-88-42
17. Fischer D, Knobf M and Durivage H (1997). The cancer chemotherapy handbook. St. Louis: Mosby. pp.514-526.
18. th Ed. Freedberg IM, Eisen AZ, Wolff K, et al. editors. McGraw-Hill, New York, pp.1642-1653.
19. Guillot B, Bessis D and Dereure O (2004). Mucocutaneous side effects of antineoplastic chemotherapy. Expert Opin Drug Saf., 3(6): 579-587.
20. Gould JW, Mercurio MG and Elmets CA (1995). Cutaneous photosensitivity diseases induced by exogenous agents. J. Am. Acad. Dermatol., 33: 551-573.
21. nd ed. Perry MC (editor). Williams & Wilkins, Baltimore, pp.595-606.
22. Huang JY, Wu CH, Shih IH and Lai PC (2004). Complications mimicking lupus flare-up in a uremic patient undergoing pegylated liposomal doxorubicin therapy for cervical cancer. Anticancer Drugs, 15(3): 239-241.
23. Impicciatore P and Choonara I (1999). Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use. Br. J. Clin. Pharmacol., 48: 15-18.
24. Koppel RA and Boh EE (2001). Cutaneous reactions to chemotherapeutic agents. Am. J. Med. Sci., 321(5): 327-235.
25. Lutzow-Holm C and Ronnevig JR (2005). Cutaneous drug reactions. Tidsskr Nor Laegeforen,. 125(18): 2483-2487.
26. Magro CM, Crowson AN and Schapiro BL (1998). The interstitial granulomatous drug reaction: a distinctive clinical and pathological entity. J. Cutan. Pathol., 25: 72-78.
27. Magro CM and Crowson AN (1995). Drugs with antihistaminic properties as a cause of atypical cutaneous lymphoid hyperplasia. J. Am. Acad. Dermatol. M., 32: 419-428.
28. Nakane M (2006). Neurotoxicity and dermatologic toxicity of cancer chemotherapy. Gan To Kagaku Ryoho., 33(1): 29-33.
29. Pejsa V, et al., (2004). No adverse effect of ABVD chemotherapy in a patient with chronic hepatitis C and Hodgkin's disease. Wien Klin Wochenschr., 116(19-20): 695-697.
30. Pillans P and Woods D (1995). Drug-associated alopecia. Int. J. Dermatol., 34: 149-158.
31. Prommer E. (2005). Pruritus in patients with advanced cancer. J. Pain Symptom. Manage, 30(3): 201-202.
32. Stephens A and Dalziel K (1998). The histopathology of drug rashes. Curr. Diagn. Pathol., 5: 138-149.
33. Susser WS, Whitaker-Worth DL and Grant-Kels JM (1999). Mucocutaneous reactions to chemotherapy. J. Am. Acad. Dermatol., 40: 367-398.
34. Sacerdoti G, Vozza A and Ruocco V (1993). Identifying skin reactions to drugs. Int. J. Dermatol., 32: 469-479.
35. Solensky R (2006). Drug hypersensitivity. Med. Clin. North Am., 90(1): 233-260.
36. Svensson CK, Cowen EW and Gaspari AA (2001). Cutaneous drug reactions. Pharmacol Rev., 53(3): 357-379.
37. Trojan A and Borelli S (2002). Adverse chemotherapy effects on skin and mucous membranes. Schweiz Rundsch Med. Prax., 91(24): 1078-1087.
38. Valks R, Garcia-Diez A and Fernandez-Herrera J (2000). Mucocutaneous reactions to chemotherapy. J. Am. Acad. Dermatol., 42(4): 699.